IBP-9414 improves GI outcomes, cuts death rates in VLBW infants
29 May 2025
bởiAudrey Abella
IBP-9414, a live biotherapeutic product (LBP), delivers gastrointestinal (GI) and mortality benefits in very low birth weight (VLBW) infants (BW 500–1,500g) born between 23 and 32 weeks gestational age in the phase III Connection study presented at PAS 2025.